Rockwell Medical, Inc. insider trading
Every open-market purchase and sale by Rockwell Medical, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Rockwell Medical, Inc.’s insiders pay?
From January 4, 2010 to April 15, 2025, 17 insiders reported 29 open-market purchases and 25 sales not made under a pre-set plan in Rockwell Medical, Inc. Twelve months after each purchase was reported, the shares were −12.7% against the S&P 500 on average (median −23.8%), over 22 purchases with a full year of prices; 27% beat the index. After sales, the shares moved +2.2% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on June 29, 2010 into $2,059 by November 2, 2026, −9.2% a year. It held shares 38% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $25,841 (+6.0% a year), and held throughout $96,651 (+14.9%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Hagelstein David A | 10% owner | 15 | +3.7% (15) | 40% | 1 | −33.5% (1) | August 29, 2012 |
| Holt Kenneth L | Director | 0 | — | — | 14 | +6.8% (14) | March 20, 2017 |
| Boyd Ronald D | Director | 0 | — | — | 4 | −11.9% (4) | December 8, 2015 |
| Chioini Robert L | Chairman, President and CEO | 2 | −47.8% (2) | 0% | 2 | +6.0% (2) | August 14, 2015 |
| Curfman Matthew J. | 10% owner | 2 | −26.6% (1) | 0% | 0 | — | July 10, 2019 |
| Rbi Private Investment II, LLC | 10% owner | 2 | −59.8% (1) | 0% | 0 | — | May 13, 2019 |
| Richmond David S. | 10% owner | 1 | −57.0% (1) | 0% | 1 | — | December 17, 2020 |
| Gupta Ajay | Chief Scientific Officer | 1 | −47.8% (1) | 0% | 0 | — | August 14, 2015 |
| Irrevocable Larson Family Investment Trust | 10% owner | 1 | — | — | 0 | — | April 15, 2025 |
| Klema Thomas E | Vice President, CFO | 0 | — | — | 1 | +22.5% (1) | January 3, 2011 |
| Paul Stuart M | Chief Executive Officer | 1 | — | — | 0 | — | July 2, 2019 |
| Pratt Raymond Dennis | VP of Drug Development | 1 | −47.8% (1) | 0% | 0 | — | August 14, 2015 |
| Ravich Mark H | Director | 0 | — | — | 1 | — | November 19, 2024 |
| Rbi Opportunities Fund, LLC | 10% owner | 0 | — | — | 1 | — | December 23, 2020 |
| Rbi Pi Manager, LLC | 10% owner | 1 | — | — | 0 | — | July 2, 2020 |
| Richmond Brothers 401(k) Profit Sharing Plan | 10% owner | 1 | — | — | 0 | — | July 23, 2019 |
| Smith Angus W. | Chief Financial Officer | 1 | — | — | 0 | — | July 2, 2019 |
When several insiders traded Rockwell Medical, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Rockwell Medical, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −49.8% against the index. After 1 selling crowd, +5.9%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 31, 2015 | 3 buying | −4.8% | −49.8% | −51.9% |
| March 31, 2011 | 3 selling | +43.0% | +5.9% | −3.1% |